A WHO grade 1 tumor is the lowest grade in the World Health Organization’s tumor classification system, indicating a slow-growing tumor that is typically considered benign or non-malignant. These tumors have a five-year survival rate around 90%, and many can be cured with complete surgical removal. If you or someone you know just received this diagnosis, it’s generally the most favorable grading a tumor can receive.
What the WHO Grading System Means
The WHO grades tumors on a scale from 1 to 4 based on how the cells look under a microscope and how they behave. Grade 1 tumors have cells that look relatively normal, divide slowly, and tend to stay in one place rather than spreading into surrounding tissue. Grade 4, by contrast, represents the most aggressive tumors with rapidly dividing, abnormal-looking cells.
Grade 1 tumors are classified as non-malignant. That doesn’t mean they’re harmless, since any growth inside the skull or spinal canal can cause problems by pressing on nearby structures. But it does mean the tumor itself isn’t cancerous in the way most people understand that word. It’s not invading healthy tissue or spreading to distant parts of the body.
Common Types of Grade 1 Tumors
The most common grade 1 brain tumor is the pilocytic astrocytoma, a slow-growing tumor that occurs most often in children and young adults. The 2021 WHO classification (the most current edition) confirms pilocytic astrocytomas retain their grade 1 status. These tumors typically grow in the cerebellum, the brain’s balance and coordination center, though they can appear elsewhere.
Meningiomas are another frequently diagnosed grade 1 tumor. They grow from the membranes surrounding the brain and spinal cord. Most meningiomas are grade 1, though the same tumor type can also be classified as grade 2 or 3 depending on how aggressive the cells appear. Several meningioma subtypes, including meningothelial, fibrous, transitional, and secretory varieties, fall into the grade 1 category.
Other grade 1 tumors in the current WHO classification include solitary fibrous tumors, certain rare diffuse astrocytomas with specific genetic alterations, and multinodular and vacuolating neuronal tumors.
Symptoms to Recognize
Because grade 1 tumors grow slowly, symptoms often develop gradually over weeks or months. Headache is the most common initial symptom. The headache pattern can vary, but it tends to worsen over time or become more frequent rather than appearing suddenly.
Seizures are the other hallmark symptom, particularly for tumors near the brain’s surface. Some people experience their first-ever seizure as the initial sign of a low-grade tumor. Beyond these two, symptoms depend heavily on where in the brain the tumor sits. A tumor in the frontal lobe might cause personality or behavioral changes. One in the temporal lobe could affect language comprehension. Tumors that block the flow of cerebrospinal fluid can cause nausea, vomiting, and vision changes due to increased pressure inside the skull.
Notably, grade 1 tumors are less likely to cause dramatic neurological problems like one-sided weakness or sudden speech loss. Because they grow slowly and push tissue aside rather than destroying it, the brain often adapts around them for a long time before noticeable deficits appear. Cognitive changes, when they occur, tend to develop gradually and relate to the tumor’s size and location.
How Grade 1 Tumors Are Treated
Surgery is the primary treatment. For grade 1 tumors that can be fully removed, complete surgical resection is often curative. Once the entire tumor is out, there may be no need for additional treatment. The goal is to remove every visible trace of the tumor, and when imaging after surgery shows no remaining tumor tissue, the disease is considered cured.
Complete removal isn’t always possible, though. Tumors at the base of the skull or near critical structures like the optic nerve can be difficult to reach without risking damage. In these cases, surgeons may remove as much as they safely can (a subtotal resection) and follow up with radiation therapy to control whatever remains. The goal shifts from eliminating the tumor to stopping its growth and relieving compression symptoms. Even with tumor tissue still present, the disease is considered controlled as long as there’s no sign of progression on follow-up imaging.
For tumors that can’t be operated on at all, whether due to their location or a patient’s overall health, radiation therapy alone can serve as the primary treatment. Stereotactic radiosurgery, which delivers a precise, concentrated dose of radiation to the tumor in a single session, is an option for smaller tumors (generally 3 centimeters or less) that sit far enough away from radiation-sensitive structures.
Survival Rates and Long-Term Outlook
The prognosis for grade 1 tumors is generally very good. Non-malignant brain tumors as a group have a five-year relative survival rate of about 90%, and that number stays above 80% even at 15 years after diagnosis. Pilocytic astrocytomas do slightly better, with a five-year survival rate around 93%.
What’s encouraging is that the outlook actually improves the longer you’ve already survived. For people with pilocytic astrocytoma who have already reached the five-year mark after diagnosis, the probability of surviving another five years rises to roughly 97%. This pattern holds for non-malignant tumors broadly, where five-year conditional survival climbs to about 95% for those who’ve already made it to year five. In practical terms, the further you get from your initial diagnosis without recurrence, the less likely the tumor is to cause problems going forward.
Follow-Up and Monitoring
Even after successful treatment, grade 1 tumors require ongoing imaging surveillance. The specific schedule depends on the tumor type and how it was treated. For tumors treated with surgery alone, MRI scans are typically performed frequently in the early years to catch any regrowth early. National guidelines for low-grade brain tumors generally recommend imaging every 3 to 6 months for the first five years, then at least every 6 to 12 months afterward.
If the tumor was completely removed and shows no sign of return after several years of clean scans, the intervals between imaging may be stretched further. Your medical team will adjust the monitoring schedule based on the specific tumor type, how much was removed, and your individual risk factors. The key point is that follow-up imaging is a standard, expected part of the process, not a sign that something has gone wrong.
How the 2021 WHO Classification Changed Things
The fifth edition of the WHO Classification of Central Nervous System Tumours, published in 2021, introduced several important updates. The grading system now places greater emphasis on molecular and genetic markers alongside traditional microscopic appearance. This means two tumors that look identical under a microscope might receive different grades based on their genetic profiles.
For grade 1 tumors specifically, the classification added new tumor types like the polymorphous low-grade neuroepithelial tumor of the young, which is exclusive to grade 1. It also refined how certain tumors are categorized. Pilocytic astrocytomas maintained their grade 1 designation, and meningiomas continue to span grades 1 through 3 depending on their cellular characteristics. The practical impact for patients is that diagnoses are now more precise, which helps doctors tailor monitoring and treatment plans more accurately.